The importance of phenoconversion when using the <i>CYP2D6</i> genotype in clinical practice-Reference-Cited by-同舟云学术

The importance of phenoconversion when using the CYP2D6 genotype in clinical practice

Published:2022-09 Issue:14 Volume:23 Page:749-752
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Cicali Emily J¹²^ORCID,Wiisanen Kristin¹²^ORCID

Affiliation:

1. Department of Pharmacotherapy & Translational Research, University of Florida, College of Pharmacy, Gainesville, FL 32608, USA

2. Center for Pharmacogenomics & Precision Medicine, University of Florida, College of Pharmacy, Gainesville, FL 32608, USA

Abstract

Tweetable abstract Clinical phenoconversion needs to be incorporated when interpreting and applying CYP2D6 results in clinical care. This article describes how this can be performed either manually or by utilizing online tools and resources. #Phenoconversion #Pharmacogenomics

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2022-0087

Reference23 articles.

1. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing

2. Complexities ofCYP2D6gene analysis and interpretation

3. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)

4. Standardizing CYP 2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group

5. The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the IGNITE ADOPT PGx investigators;Clinical and Translational Science;2024-08

2. The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics;Pharmacopsychiatry;2024-02-14

3. Therapeutic Drug Monitoring in Children and Adolescents: Findings on Fluoxetine from the TDM-VIGIL Trial;Pharmaceutics;2023-08-25

4. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study;International Journal of Clinical Pharmacy;2023-05-11

5. The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses;Frontiers in Pharmacology;2023-02-21